Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Universal Beteiligungs und Servicegesellschaft mbH has invested in Kiniksa Pharmaceuticals International, purchasing 9,140 shares valued at $253,000 in Q2. Other institutional investors have also acquired stakes. Insider sales include CAO Michael R. Megna and CEO Sanj K. Patel. Analysts have mixed ratings, with a moderate buy consensus and a $52 average price target. Kiniksa's stock opened at $42.49, with a market cap of $3.22 billion. Recent earnings missed estimates, but revenue increased by 61.2% year-over-year.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 9,140 shares of the company's stock, valued at approximately $253,000.

Several other institutional investors have also recently made changes to their positions in the company. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at $33,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth $42,000. Robeco Institutional Asset Management B.V. acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $233,000. Pallas Capital Advisors LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $236,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $252,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, CAO Michael R. Megna sold 50,490 shares of the business's stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the sale, the chief accounting officer owned 27,046 shares of the company's stock, valued at $1,051,278.02. The trade was a 65.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sanj K. Patel sold 97,390 shares of the firm's stock in a transaction that occurred on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the transaction, the chief executive officer directly owned 111,794 shares of the company's stock, valued at $4,340,961.02. The trade was a 46.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 622,513 shares of company stock worth $23,607,641. 53.48% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a research note on Thursday, September 25th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, November 2nd. Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Finally, TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a "buy" rating and a $60.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $52.00.

Check Out Our Latest Analysis on KNSA

Kiniksa Pharmaceuticals International Trading Down 0.1%

Shares of KNSA stock opened at $42.49 on Friday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $42.98. The stock has a 50 day simple moving average of $39.09 and a 200-day simple moving average of $33.46. The company has a market cap of $3.22 billion, a price-to-earnings ratio of 94.42 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same period last year, the company earned ($0.18) earnings per share. The business's revenue for the quarter was up 61.2% compared to the same quarter last year. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

(Free Report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?

Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.

While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here